NEW YORK - Pfizer and BioNTech on Thursday announced that they have formally submitted a request to U.S. regulators for emergency approval of their COVID-19 vaccine for children ages 5 to 11.The companies previously submitted data to the U.S.
Food and Drug Administration from a late-stage trial involving more than 2,2600 participants, which the agency has been reviewing.
FILE - A nurse gives a girl a dose of the Pfizer vaccine at a COVID-19 vaccine clinic at Lyman High School on Aug. 9, 2021, in Longwood, Florida. (Photo by Paul Hennessy/SOPA Images/LightRocket via Getty Images) The Pfizer COVID-19 vaccine is currently available in the U.S.